GIMBHI: LifeStance Health (LFST) Q2 2026 Earnings

Uncategorized
Written By

Sources: LifeStance Health 10-Q, Claude

Additional Information: Filed August 6, 2026

Financial Performance

  • Revenue $435.4M (26% YoY, 8% sequential vs Q1)

  • H1 2026 revenue $838.8M (24% YoY)

  • Income from operations $30.7M vs $(3.0)M loss YoY

  • Net income $23.6M vs $(3.8)M loss YoY

  • Adjusted EBITDA $66.0M (94% YoY, 15.2% margin)

  • Q2 adj. EBITDA margin 15.2%, up from 9.8% YoY (massive operating leverage inflection)

  • H1 adj. EBITDA margin 14.0%, blowing past 12.7% Q1 level

  • Center Margin $153.0M (35.2% of revenue, up from 33.7% in Q1)

  • G&A grew only 11% while revenue grew 26% (continued fixed-cost leverage)

  • SBC fell 6% YoY to $19.7M (still 4.5% of revenue)

  • EPS $0.06 basic and diluted vs $(0.01) YoY

  • $225.9M cash (up from $194.8M in Q1), $275.5M term loan, $100M revolver undrawn

Unit Economics & Engagement

  • 2.6M visits completed in Q2 (5.1M H1)

  • 8,542 licensed clinicians (net adds of 193 sequential from Q1, 834 YoY)

  • Growth decomposition: ~19% volume + ~7% rate (rate acceleration vs Q1’s ~3%)

  • Revenue per visit ~$167 (up from ~$161 in Q1, meaningful rate lift)

  • Revenue per clinician ~$204K quarterly, ~$815K annualized

  • Contribution after center costs ~$18K per clinician per quarter (Q2)

  • Rate acceleration is the biggest single takeaway from this quarter

Payor Leverage & Mix

  • Commercial 88% of revenue, Government 7% (up from 6% in Q1), Self-pay 4%

  • Two payors are 14% and 15% of revenue (Payor A ticked up from 13%)

  • Continued strategy of terminating low-volume payor contracts to force rate improvement

  • Rate parity between virtual and in-person still secured

  • OBBBA Medicaid changes still shrugged off (Medicaid exposure remains tiny)

  • Government revenue growing faster than commercial (7% mix vs 5% YoY)

Network & Operations

  • W-2 clinician model with 8,542 providers, up from 8,349 in Q1

  • Friendly-PC structure unchanged: MSA + STR agreements enable multi-state operation

  • Multi-channel CAC continues: payor referrals, PCP/specialist, internal, online

  • Material weaknesses in internal controls still unresolved (now going on 7 years)

  • Only one remediation completed this quarter (access management controls)

  • CEO/CFO still formally certify disclosure controls “not effective”

Capital Allocation & M&A

  • $100M buyback fully deployed by end of Q2 ($97.6M repurchased YTD, ~$2.8M remaining)

  • Q2 alone: 6M shares repurchased at $8.02 avg (vs Q1’s $7.01 avg, stock up 14%)

  • 3 tuck-in acquisitions H1 for $13.1M total ($9.4M cash + $3.6M contingent)

  • Acquisition pace picking up vs Q1 (3 deals vs 2)

  • Buyback price rising as market re-rates the operating leverage story

  • $108.5M unrecognized stock comp over 2.2 years (~$49M/year run rate, declining from Q1)

Balance Sheet

  • $225.9M cash (rebounded from $194.8M Q1, +$31M despite $48.5M buyback)

  • Operating cash flow $133M H1 vs $61M H1 2025 (117% YoY improvement)

  • Real cash generation showing up in the numbers now

  • $275.5M term loan at SOFR+3% (~7.3% effective)

  • $100M revolver still undrawn

  • Net leverage covenant 4.5x; interest coverage 3.0x; in compliance

  • Goodwill $1.30B vs total assets $2.18B

  • LifeStance trade name = $171M intangible, 22.5-year useful life

  • TPG + Summit ownership down to 35.4% from 43.6% in Q1 (secondary offering completed in Q2)

  • Sponsor overhang shrinking materially

Market Position & Strategy

  • Largest national outpatient mental health platform by clinician count

  • Selling stockholder offerings completed in Q1 and Q2 (sponsor exit progressing)

  • Continued organic + productivity-led growth playbook

  • No material M&A slowdown, tuck-ins accelerating modestly

  • Effective tax rate 14.0% in Q2 (down from 27.9% in Q1) driven by favorable equity award treatment

The Connective Thesis

  • LifeStance’s Q2 is the “we told you so” quarter, adj. EBITDA margin jumped from 12.7% to 15.2% sequentially, exactly the operating leverage story management has been pitching

  • Rate acceleration from ~3% to ~7% YoY is the most underappreciated data point, suggests the “terminate low-volume payors” strategy is actually working

  • Sponsor overhang materially reduced (43.6% → 35.4%), removing one of the biggest structural headwinds on the stock

  • Cash generation nearly doubled H1 YoY ($133M vs $61M), buybacks fully deployed at rising prices

  • For startups: this is what a mental health services business looks like at the operating leverage inflection point, ~25% top line + 15%+ EBITDA margin is achievable but requires 8K+ clinicians and 5+ years of payor contracting

  • The unresolved material weaknesses remain a category-wide warning about integration debt from roll-ups

  • Government mix inching up (5% → 7%) worth watching as OBBBA implementation approaches 2027-2028

  • Q2 confirms Q1 wasn’t a one-off, the operating leverage story is real and accelerating